Key Takeaways ODFL's Q3 earnings estimate was cut 10.2% to $1.23, signaling weaker near-term performance. Shares dropped 26.2% in a year versus a 22.7% fall in the Transportation - Truck industry. LTL tons per day fell 9.3%, pressuring revenue growth despite pricing discipline.Old Dominion Freight Line’s (ODFL) shares have had an unimpressive run in a year. Shares of this trucking company have plunged 26.2% in the same period, underperforming its industry’s 22.7% fall.Image Source: Zacks Investment Researc ...

Core Insights - Sanofi and Regeneron received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending the approval of Dupixent for chronic spontaneous urticaria in adults and adolescents [1][2] Group 1: Product Approval and Market Potential - The recommendation targets patients aged 12 years and older with moderate-to-severe chronic spontaneous urticaria who have not responded adequately to antihistamines and are naive to anti-immunoglobulin E therapy [2] - Dupixent was previously approved by the FDA for this indication in April 2025, marking it as the first new targeted therapy for chronic spontaneous urticaria in over a decade [3][4] - Dupixent is already approved for multiple conditions, including severe chronic rhinosinusitis, severe asthma, and atopic dermatitis, with its approval for chronic spontaneous urticaria being its seventh indication in the U.S. [4][11] Group 2: Clinical Data and Efficacy - The positive opinion for Dupixent's approval in the EU is based on Phase III studies that demonstrated significant reductions in itch and hives compared to placebo [9][10] - Both primary and secondary endpoints were met in the studies, showing improved disease control with Dupixent [10] - Safety data from the studies were consistent with the known safety profile of Dupixent in its other approved indications [11] Group 3: Financial Performance - In the first half of 2025, Dupixent generated global product sales of €7.3 billion, reflecting a growth of 20.7% at constant exchange rates [7][13] - Sanofi projects that Dupixent could achieve approximately €22 billion in sales by 2030 [7][13] Group 4: Market Context - Year to date, Sanofi's shares have decreased by 2.5%, while the industry has seen a growth of 0.9% [5]

Group 1 - The Sprott Gold Miners ETF (SGDM) has reached a 52-week high and is up 121.09% from its 52-week low price of $26.60 per share [1] - The underlying index, Solactive Gold Miners Custom Factors Index, tracks larger-sized gold companies listed on Canadian and major U.S. exchanges, with an annual fee of 50 basis points [1] - The recent performance of gold is influenced by geopolitical tensions and increased demand for safe-haven assets, alongside the Federal Reserve's rate cuts [2] Group 2 - SGDM is expected to maintain strong performance in the near term, indicated by a positive weighted alpha of 104.17, suggesting potential for further gains [3]

Citizens Financial Group (CFG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since ...

Core Viewpoint - Asbury Automotive Group (ABG) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Asbury Automotive reflects an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in a company's future earnings potential, as shown by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for fair value calculations [5]. - Rising earnings estimates and the subsequent rating upgrade for Asbury Automotive suggest an improvement in the company's underlying business, which should encourage investors to drive the stock price higher [6]. Zacks Rank System - The Zacks Rank stock-rating system categorizes stocks into five groups based on four earnings estimate-related factors, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [8]. - The upgrade of Asbury Automotive to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Earnings Estimate Revisions for Asbury Automotive - For the fiscal year ending December 2025, Asbury Automotive is expected to earn $27.39 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 2.2% over the past three months [9].

Investors might want to bet on Cidara Therapeutics (CDTX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

Xperi (XPER) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a ...

Core Viewpoint - Couchbase, Inc. (BASE) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Couchbase's Earnings Outlook - The upgrade for Couchbase reflects an improvement in the company's underlying business, suggesting that investor sentiment regarding this trend could drive the stock price higher [5][10]. - For the fiscal year ending January 2026, Couchbase is expected to earn -$0.14 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 0.5% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks averaging a +25% annual return since 1988 [7]. - The upgrade of Couchbase to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Enel SpA (ENLAY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ...

Investors might want to bet on Inspira Technologies OXY B.H.N. Ltd. (IINN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estim ...